Response to dabrafenib after progression on vemurafenib in a patient with advanced BRAF V600E-mutant bronchial adenocarcinoma.

Publikation

Response to dabrafenib after progression on vemurafenib in a patient with advanced BRAF V600E-mutant bronchial adenocarcinoma.

Wissenschaftlicher Artikel/Review - 18.11.2014

Schmid S, Siano Marco, Joerger M, Rodriguez Regulo, Müller J, Früh M

Zitation

Schmid S, Siano M, Joerger M, Rodriguez R, Müller J, Früh M. Response to dabrafenib after progression on vemurafenib in a patient with advanced BRAF V600E-mutant bronchial adenocarcinoma. Lung Cancer 2014; 87:85-7.

Art

Wissenschaftlicher Artikel/Review (Englisch)

Zeitschrift

Lung Cancer 2014; 87

Veröffentlichungsdatum

18.11.2014

eISSN (Online)

1872-8332

Seiten

85-7

Kurzbeschreibung/Zielsetzung

We present the case of a patient with rapidly accelerated fibrosarcoma gene F (BRAF) mutated adenocarcinoma of the lung, responding to BRAF inhibitor dabrafenib after progressing on vemurafenib followed by docetaxel. The present case illustrates the potential benefit of successful rechallenge with a BRAF inhibitor, a well known phenomenon observed in other oncogenic driven molecular subtypes of non-small cell lung cancer (NSCLC) such as epidermal growth factor receptor mutation. Rechallenge with a BRAF inhibitor in BRAF mutated NSCLC should be considered, particularly in the absence of alternative therpateutic options.